Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of REGN20566 in Adult Participants With Overweight or Obesity
This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it.
The study will be split into two parts, Part A and Part B.
The study is looking at:
- What side effects REGN20566 might cause
- How much REGN20566 is in the blood at different times
- If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Total planned duration of trial participation for each participant (excluding screening period):
- Part A: approximately 16 weeks
- Part B: approximately 27 weeks
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Has a body mass index 27-40 kg/m2, inclusive, at screening visit or prior to randomization
- Healthy volunteers with obesity
Key Exclusion Criteria:
- A self-reported change of body weight >5 kg within 90 days of screening visit
- History of type 1 or 2 diabetes, or bariatric surgery
- Hemoglobin A1c (HbA1c) ≥6.5% at the screening visit
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease
- Received a nutrient stimulating hormone (NuSH)-based therapy (eg, Glucagon-like peptide-1 receptor agonist [GLP-1RA]) within 6 months of the screening visit
- Planned initiation of NuSH-based therapy, bariatric surgery, or alternative procedures aimed at reducing weight or altering of body composition during the duration of the trial
- Received an anti-obesity medication within 90 days of screening visit
Note: Other protocol defined Inclusion/ Exclusion Criteria apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Del A
|
Administered per the protocol Administered per the protocol |
|
Placebo komparator: Part B
|
Administered per the protocol Administered per the protocol |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Severity of TEAEs
Tidsramme: Up to 16 weeks
|
Part A |
Up to 16 weeks
|
|
Occurrence of TEAEs
Tidsramme: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
|
Severity of TEAEs
Tidsramme: Up to 27 weeks
|
Part B |
Up to 27 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Concentration of REGN20566 in serum
Tidsramme: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Concentration of REGN20566 in serum
Tidsramme: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN20566
Tidsramme: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Magnitude of ADA to REGN20566
Tidsramme: Baseline through week 16
|
Part A |
Baseline through week 16
|
|
Occurrence of ADA to REGN20566
Tidsramme: Baseline through week 27
|
Part B |
Baseline through week 27
|
|
Magnitude of ADA to REGN20566
Tidsramme: Baseline through week 27
|
Part B |
Baseline through week 27
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- R20566-OB-2626
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .